- ISIN
- US08659B1026
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Jan 30, 2025
Highlights
- Market Cap
- $577.22M
- Enterprise Value
- $541.00M
- EPS (TTM)
- -$1.69
- Total Revenue (TTM)
- $119.01M
- Gross Profit (TTM)
- $69.40M
- EBITDA (TTM)
- -$72.86M
- Year Range
- $8.80 - $32.71
- Target Price
- $19.83
- ROA (TTM)
- -24.96%
- ROE (TTM)
- -28.46%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $18.41M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BBNX Performance Chart
Beta Bionics, Inc (BBNX) is down 57.9% since the beginning of the year. At $13 per share, BBNX is trading 60.8% below its 52-week high of $33.
Loading charts...
Compare this symbol against anything
Returns By Period
Beta Bionics, Inc (BBNX) has returned -57.89% so far this year and -21.77% over the past 12 months.
Beta Bionics, Inc
- 1D
- -10.09%
- 1M
- -23.45%
- 6M
- -7.23%
- YTD
- -57.89%
- 1Y
- -21.77%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -30.24%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
BBNX Monthly Returns History
Based on dividend-adjusted daily data since Jan 30, 2025, BBNX's average daily return is +0.01%, while the average monthly return is +0.82%. At this rate, an investment would double in approximately 7.1 years.
Historically, 53% of months were positive and 47% were negative. The best month was May 2025 with a return of +56.0%, while the worst month was Jan 2026 at -54.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BBNX closed higher 48% of trading days. The best single day was May 7, 2025 with a return of +26.6%, while the worst single day was Jan 9, 2026 at -37.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -54.61% | -8.68% | -20.67% | 1.80% | 18.82% | 29.29% | -18.12% | -57.89% | |||||
| 2025 | 8.23% | -11.93% | -41.63% | -9.72% | 56.02% | -15.55% | 15.32% | 12.21% | 5.47% | 36.99% | 15.14% | -2.78% | 38.50% |
Benchmark Metrics
Beta Bionics, Inc has an annualized alpha of -22.38%, beta of 1.68, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since January 30, 2025.
- This stock participated in 384.44% of S&P 500 Index downside but only 154.27% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -22.38%
- Beta
- 1.68
- R²
- 0.11
- Upside Capture
- 154.27%
- Downside Capture
- 384.44%
Return for Risk
Risk / Return Rank
BBNX ranks 34 for risk / return — above 34% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Beta Bionics, Inc (BBNX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBNX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.71 | ||
| Sortino ratioReturn per unit of downside risk | -1.84 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.25 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.33 | 2.00 | -2.33 |
| Martin ratioReturn relative to average drawdown | -0.53 | 8.49 | -9.02 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Beta Bionics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Beta Bionics, Inc was 72.30%, occurring on Apr 10, 2026. The portfolio has not yet recovered.
The current Beta Bionics, Inc drawdown is 59.89%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-72.30%Apr 2026 | 3mo 1d | — | 6mo 25dJan 2026 - now | — |
-59.22%Apr 2025 | 2mo 4d | 5mo 4d | 7mo 8dFeb 2025 - Sep 2025 | 2025 selloff2025 |
-26.05%Sep 2025 | 11d | 1mo 3d | 1mo 14dSep 2025 - Oct 2025 | — |
-10.16%Dec 2025 | 12d | 14d | 26dNov 2025 - Dec 2025 | — |
-9.96%Nov 2025 | 1d | 5d | 6dNov 2025 - Nov 2025 | — |
Drawdown Indicators
| BBNX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.30% | -56.78% | -15.52% |
Max Drawdown (1Y)Largest decline over 1 year | -72.30% | -9.10% | -63.20% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -59.89% | -1.58% | -58.31% |
Average DrawdownAverage peak-to-trough decline | -37.22% | -10.70% | -26.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.83% | 2.14% | +42.69% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Beta Bionics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Beta Bionics, Inc is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BBNX relative to other companies in the Medical Devices industry. Currently, BBNX has a P/S ratio of 4.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BBNX in comparison with other companies in the Medical Devices industry. Currently, BBNX has a P/B value of 2.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BBNX
Add Beta Bionics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BBNX